FOXP3 and systemic lupus erythematosus: Further, in new-onset SLE patients with active disease, treatment with GCs and cyclophosphamide resulted in a significant increase in the percentage of CD4+CD25high cells (about 1.3-fold), but not in the percentage of CD4+FoxP3+ cells [137].